# Sermorelin Side Effects in the Research Literature: What Is Reported > Sermorelin side effects in the research literature: the tolerability signals, the GH/IGF-1 mitogenic theoretical caution, the limited long-term adult data, and the WADA status — reported, not advised. What the studies and editorials actually say about tolerability, the theoretical GH/IGF-1 risk, the limits of adult long-term data, and the anti-doping status — carved out plainly. ## The short version This page summarizes what the literature reports about sermorelin side effects — it is not safety advice and not a green light. The headline caution is mechanistic: growth hormone and IGF-1 (a growth signal the liver makes when GH rises) are mitogenic, meaning they encourage cells to divide, so chronically raising them is a recognized theoretical safety consideration for any GH-axis intervention. In the studies summarized here, sermorelin worked through the body's own feedback-regulated bursts, and short adult studies reported it well-tolerated [2] — but long-term adult safety data are limited, and authorities have cautioned against routine anti-aging use [5]. ## What the studies reported on tolerability ### What are the side effects of sermorelin? Because GH and IGF-1 are mitogenic, chronically raising them is a recognized theoretical safety consideration; long-term adult safety data are limited, and authorities have cautioned that secretagogue use for aging is not yet evidence-justified [5]. Findings here are reported, not advised. In the controlled adult studies, the secretagogue route was generally well-tolerated over the short durations examined. In older men, 14 days of twice-daily GHRH(1-29) raised GH and IGF-1 without changing fasting glucose [2]; in the 20-week cognition RCT of a GHRH analog, adverse events were mild and IGF-1 stayed within the physiologic range [6]. These are reassuring short-horizon signals — not a long-term safety profile. ## The theoretical GH/IGF-1 risk, stated plainly The central safety consideration for any GH-axis intervention is theoretical and mechanistic. GH and IGF-1 are mitogenic — they drive cell growth and division — so any sustained elevation is theorized to carry oncologic (cancer-related) risk. This caution applies even though sermorelin acts via the body's own feedback-regulated pulsatile secretion rather than by flooding the system with hormone [12]. The distinction matters but does not erase the concern. Preserved somatostatin and IGF-1 feedback means the axis can still restrain itself [8][12], which is the physiologic argument for a secretagogue over direct hormone. But "more physiologic" is an argument about mechanism, not a long-term outcome study, and the digest keeps that line visible. ## Limited adult data, and the 'not yet ready' verdict The honest constraint is the evidence base itself. Long-term tolerability data specifically for adult anti-aging use remain limited; the strongest adult results are short studies and a single 20-week cognition trial of a related analog [2][6]. An Annals of Internal Medicine editorial reviewed the field and judged the use of growth hormone secretagogues to prevent or treat the effects of aging "not yet ready for prime time" [5]. That verdict is the safety frame for the anti-aging marketing. The body-composition and longevity claims circulating around sermorelin run ahead of controlled long-term data; where rigorous body-composition evidence exists, it largely belongs to the stabilized analog tesamorelin in specific populations [6], not to native sermorelin in healthy adults. One point of context, stated plainly so it is not mistaken for a safety warning: sermorelin is no longer a marketed branded drug but a compounded preparation. It was withdrawn from the US market in 2008 for commercial reasons — not for safety or efficacy — and is now prepared by compounding pharmacies under USP <797> sterile-compounding standards [5]. "Compounded rather than branded" describes its supply status; it does not, by itself, signal that the molecule is unsafe. ## Anti-doping status and ineffective oral forms Sermorelin is prohibited in sport. Growth hormone secretagogues, including GHRH and its analogues, appear on the WADA Prohibited List under hormone and metabolic modulators (S2), and dedicated detection methods exist. Longitudinal anti-doping work has shown that IGF-I and the calculated GH-2000 score can detect GHRH administration in men whose values exceed individually calculated thresholds, though menstrual-cycle variation made the markers harder to evaluate in women [11]. Athletes face anti-doping consequences. A practical caution closes the page: oral, sublingual, and troche "sermorelin" products are widely criticized as ineffective because peptides are degraded in the gut and poorly absorbed across mucosa — consistent with the very low (~3-5%) intranasal bioavailability reported for GHRH(1-29) [3]. None of this is medical advice; it is the published record, reported for readers who want the science straight. --- A two-value woodblock reading of the sermorelin record — the GHRH(1-29) findings in men, aging, sleep and cognition pressed into plain inked panels and each figure cut back to the study that measured it, the formerly-approved-then-withdrawn history set straight and the spot where the adult anti-aging data thin left openly uncut; no clinic behind the block and nothing here dosed, dispensed, or sold.